Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189.

View in: PubMed

subject areas

Adolescent
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Child
Child, Preschool
Follow-Up Studies
Humans
Infant
Interleukin-2
Isotretinoin
Male
Neuroblastoma
Recombinant Proteins

authors with profiles

Susan L. Cohn